|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Abbott Laboratories, of Abbott Park, Ill., disclosed new results of two analyses from a Phase III study of Humira (adalimumab) in ankylosing spondylitis (AS). The first analysis showed the U.S.-approved arthritis drug maintained the reduction of signs and symptoms in patients at 12 weeks through 52 weeks of treatment. A second analysis showed the drug rapidly and significantly reduced pain and fatigue as early as two weeks compared with placebo, and that the improvement was maintained for at least 24 weeks. Data were presented at the annual congress of the European League Against Rheumatism in Amsterdam, the Netherlands, and they follow the recent approval by the ...
Related newspaper, magazine, and journal articles:
|
|
Article: Single Center Results From Hemopure(R) Pivotal Phase ...
PR Newswire;
January 27, 2002 ;
700+ words
... ... participated in Biopure Corporation's pivotal Phase III clinical trial of Hemopure(R) [hemoglobin glutamer ... Critical Care Medicine's 31st Annual Congress in San Diego, Cal. The Phase III trial is a multinational, randomized, red blood ...
|
|